LOGIN JOIN SHARECAFE SIGN UP FOR OUR NEWSLETTER ADVERTISE
share cafe logo  
 
SHARECAFE COMMENTARY

Stocks In The Baby-Making Business
BY TIM BOREHAM - 01/09/2017 | VIEW MORE ARTICLES BY TIM BOREHAM

Get More Commentary, Discussion & Market Information On -

VRT - VIRTUS HEALTH LIMITED
MVF - MONASH IVF GROUP LIMITED


A pregnant pause, or the advent of a more permanent decline?

The country’s biggest providers of assisted reproductive services - ARS to friends - are contending with a downturn in the baby-making business, even though the age of an average mum has crept up to 31.

In the case of Virtus, the biggest provider, the average age of a client is a mature 37, by which the biological clock is ticking at two minutes to midnight. The dynamics that have delayed pregnancy – such as enhanced careers for women and twenty somethings staying home longer – remain intact.

In the eastern seaboard market in which it operates, Virtus reported a 3.7 per cent decline in IVF cycles on a like-for-like basis to 15,776 for the 2016-17 year. The Victoria focused Monash IVF (the second biggest provider nationally) reported a 3.1 per cent decline in local cycles to 8902.

Virtus reckons the overall market is down 0.24 per cent, while Monash IVF estimates the decline at 0.8 per cent.

Both providers are losing market share: Virtus from 43.9 per cent to 42 per cent and Monash IVF from 22.9 per cent to 22.4 per cent.

It’s not so much a case of the ARS falling out of the market, but a migration to low providers and notably the clinics set up by bulk-billing newcomer Primary Health. The patchy economy means couples have either deferred treatment, or chosen the discount option.

While Monash IVF does not play in the low-cost sector, five years ago Virtus set up the first of its no-frills chains, under the banner of The Fertility Clinic (TFC). While Virtus’s full-service activity declined 3.1 per cent, TFC cycles increased by 3.9 per cent like-for-like. After a poor first half, TCF’s cycles surged 24 per cent after the company discounted in some geographies to compete with Primary.

Virtus chief Sue Channon estimates 20-30 per cent of cycles are now low cost, despite the government reducing Medicare benefits.

Rather like flying Jetstar over Qantas, the discount experience differs only at the edges such as access to genetic testing services. The success rates are similar, although women deemed as unsuitable are up-sold to the deluxe option that may skew the comparison.

“We triage very carefully,” Channon says. “We would not put some patients through this low cost model.”

As for the overall industry, Channon says that industry growth rates have always yo-yoed. While growth over the last five years has averaged 2.2 per cent, in 2011 the cycles sunk -6 per cent and then in 2012 rebounded t 9 per cent. “The overall long term compound average growth rate sits at 3 per cent but with lots of variations,” she says.

“Generally the global demographics support growth in ARS. One in six couple have an issue with fertility. When there’s less activity you have pent up demand.” Monash IVF has fared better than Virtus in maintaining its bottom line, reporting 2.9 per cent net profit increase to $29.6m on a 0.9 per cent revenue decrease to $155.2m.

Monash has operations in Malaysia and has expanded into Tasmania – a state that could do with a few more youngsters – through its minority holding in Fertility Tasmania.

Virtus, reported net earnings of $28.1m, down 14.6 per cent and revenue of $256.5m, down 1.8 per cent. The company also operates in Ireland, Singapore and Denmark, Pending the next assisted baby boom, the duo may struggle to maintain their mojo.

Monash IVF chief James Thiedman reports “no apparent reversion of ARS industry growth rates to long-term market growth rates in the first two months of financial year 2017-18.”

The star IPO of 2013 and the first listed IVF company globally, Virtus has responded with a $5m cost-cutting drive focused on non-clinical areas such as marketing. A special plea though: spare those promotional pens with a moving ‘sperm’ and ‘egg’ encased in fluid.



View More Articles By Tim Boreham

The New Criterion is authored by Tim Boreham.

Many readers will remember Boreham as author of the Criterion column in The Australian newspaper, for well over a decade. He also has more than three decades' experience of business reporting across three major publications.

Tim Boreham has now joined Independent Investment Research and is proud to present The New Criterion, which will honour the style and purpose of the old column. These were based on covering largely ignored small to mid cap stocks in an accessible and entertaining manner for both retail and professional investors.

Disclaimer: The author nor Independent Investment Research have received a fee or any kind of inducement for this article. The New Criterion is not intended as specific investment advice and readers should contact a licensed financial adviser.



 

RECENTLY ADDED TO SHARECAFE


 › Video - Geoff Wilson Moves Into Global Equities
 › Volkswagen Order $48 Billion In Batteries, That's A Lot Of Graphite!
 › What Would Warren Buffett Think Of The Banking Royal Commission?
 › Second Half Critical For TechnologyOne
 › Market At Midday On Wednesday
 › Why The 'New Age' Businesses Are Still Too Expensive
 › The Digital Music Streaming Win-Win-Win
 › New Target for A Top On The Dow
 › Your $2 Million Choice Picks
 › Overnight: Geopolitics
 › CLH - Morgans rates as Hold
 › JHX - Morgan Stanley rates as Equal-weight
 › HSO - Credit Suisse rates as Neutral
 › Santos Rejects Revised Takeover Offer
More ShareCafe   

GET THE SHARECAFE BREAKFAST BRIEFING


Delivered free to your inbox before the market opens each trading day. Sign up below +

SHARECAFE VIDEO


Wilson moves into Global Equities

More video